Sci—Fri PM: Dosimetry—06: Commissioning of a 3D patient specific QA system for hypofractionated prostate treatments

• Published in: Medical physics (Lancaster) 2014-08, Vol.41 (8Part3), p.27-27
• Main Authors: Rivest, R, Venkataraman, S, McCurdy, B
• Format: Article
• Language: English
• Subjects: COMMISSIONING; Computer software; DATASETS; FILM DOSIMETRY; Ion beam detectors; IONIZATION CHAMBERS; Medical treatment planning; Model validation; PATIENTS; PHANTOMS; PLANNING; PROSTATE; RADIATION DOSE DISTRIBUTIONS; RADIOLOGY AND NUCLEAR MEDICINE; Three dimensional image processing; Three dimensional sensing; VERIFICATION
• ISSN: 0094-2405; 2473-4209
• DOI: 10.1118/1.4894961

The objective of this work is to commission the 6MV‐SRS beam model in COMPASS (v2.1, IBA‐Dosimetry) and validate its use for patient specific QA of hypofractionated prostate treatments. The COMPASS system consists of a 2D ion chamber array (MatriXXEvolution), an independent gantry angle sensor and associated software. The system can either directly calculate or reconstruct (using measured detector responses) a 3D dose distribution on the patient CT dataset for plan verification. Beam models are developed and commissioned in the same manner as a beam model is commissioned in a standard treatment planning system. Model validation was initially performed by comparing both COMPASS calculations and reconstructions to measured open field beam data. Next, 10 hypofractionated prostate RapidArc plans were delivered to both the COMPASS system and a phantom with ion chamber and film inserted. COMPASS dose distributions calculated and reconstructed on the phantom CT dataset were compared to the chamber and film measurements. The mean (± standard deviation) difference between COMPASS reconstructed dose and ion chamber measurement was 1.4 ± 1.0%. The maximum discrepancy was 2.6%. Corresponding values for COMPASS calculation were 0.9 ± 0.9% and 2.6%, respectively. The average gamma agreement index (3%/3mm) for COMPAS reconstruction and film was 96.7% and 95.3% when using 70% and 20% dose thresholds, respectively. The corresponding values for COMPASS calculation were 97.1% and 97.1%, respectively. Based on our results, COMPASS can be used for the patient specific QA of hypofractionated prostate treatments delivered with the 6MV‐SRS beam.